A study of the clinical effect of secukinumab combined with calcipotriol ointment in the treatment of moderate-to-severe psoriasis
Objective To study the efficacy of secukinumab combined with calcipotriol ointment in the treatment of moderate-to-severe psoriasis.Methods A total of 110 patients with moderate-to-severe psoriasis were randomly divided into two groups by digital table method,namely the control group(treated with capotriol ointment alone,55 cases)and the study group(treated with secukinumab combined with capotriol ointment,55 cases).Both groups were compared in terms of efficacy,symptom improvement time,psoriasis area and severity index(PASI)score,levels of inflammatory cytokines[interleukin-17(IL-17),tumor necrosis factor-α(TNF-α)and interleukin-23(IL-23)],and occurrence of adverse reactions.Results Compared with the control group(81.82% ),the total effective rate of the study group(96.36% )was higher(P<0.05).The improvement time of skin desquamation,scaling,erythema and pruritus in the study group were(9.66±1.77),(10.44±1.72),(11.15±1.22)and(10.35±1.40)d,which were shorter than(13.50±1.66),(12.71±1.66),(13.55±1.17)and(13.50±1.51)d in the control group(P<0.05).Before treatment,there was no significant difference in PASI scores between the two groups(P>0.05).After 1 and 4 weeks of treatment,the PASI scores of the study group were(15.20±3.89)and(10.02±2.33)points,which were lower than(23.50±5.44)and(15.60±2.47)points of the control group(P<0.05).After treatment,the study group had IL-17 of(96.44±11.82)pg/ml,TNF-α of(97.66±10.55)μg/L and IL-23 of(189.66±15.00)pg/ml,while the control group had IL-17 of(103.55±14.28)pg/ml,TNF-α of(105.30±11.84)μg/L,and IL-23 of(201.33±20.28)pg/ml.The levels of inflammatory cytokines of IL-17,TNF-α and IL-23 were lower in the study group(t=2.8445,3.5729,3.4311;P=0.0053,0.0005,0.0009<0.05).Compared with the control group(20.00% ),the incidence of adverse reactions in the study group(3.64% )was lower(P<0.05).Conclusion The combination of secukinumab and calcipotriol ointment in the treatment of patients with moderate-to-severe psoriasis has achieved precise efficacy,high clinical safety and effectiveness,which can accelerated the recession of the patient's symptoms,reduce the level of inflammatory cytokines,and improved the patient's immune function.It is worthy of use.
万方数据
维普
